CTOs on the Move

454 Life Sciences, a Roche company

www.454.com

 
454 Life Sciences' system enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.454.com
  • 15 Commercial St
    Branford, CT USA 06405
  • Phone: 203.871.2300

Executives

Name Title Contact Details

Similar Companies

Ibidi

Ibidi is a Verona, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Imara

Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.

SuperGen

SuperGen Inc. is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Takeda San Francisco

Takeda San Francisco is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarveda Therapeutics

Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.